Health Care & Hospital Law
Jun. 8, 2023
$39M deal ends investors suit against BioMarin Pharmaceutical
BioMarin was accused of misrepresenting to investors that the Food and Drug Administration was going to approve its new drug, valrox, and when it would be approved.
BioMarin Pharmaceutical Inc., a medical company seeking to be the first in the nation to sell a hemophilia gene therapy, and the company’s investors asked a federal judge Wednesday to grant preliminary approval for a $39 million settlement to resolve securities claims.
Senior U.S. District Judge William H. Orrick took the matter under submission and said he would issue a written order.
BioMarin was accused of m...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In